ECOG-ACRIN Cancer Research Group
@eaonc
Followers
6K
Following
4K
Media
4K
Statuses
9K
Biomarker-driven medical research involving adults who have or are at risk of developing cancer
1400+ member research sites
Joined November 2013
Attending #SABCS25 this week? View this helpful guide to @eaonc research at the meeting, including data from an exciting TAILORx correlative science initiative. More: https://t.co/YmeYSU6eER
#BreastCancer #bcsm
ecog-acrin.org
Learn about the discoveries set to be shared at the 2025 San Antonio Breast Cancer Symposium
0
0
0
#FindingsFriday: ICYMI, yesterday at #SABCS25, @drjenspecht presented results from the EA1183/FEATURE trial in bone-dominant metastatic #BreastCancer. Read more about this major advance in #cancer imaging: https://t.co/7wj58T6bDv
#bcsm #mbc
ecog-acrin.org
Learn more about this major advance in cancer imaging that improves treatment decision-making and opens access to clinical trials for patients with metastatic breast cancer that has advanced primar...
0
0
1
The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: https://t.co/4l7zZqiy2W cc: @nsc_natalie, @mtmdphd, @VincentRK, @NorthTxMSG
0
2
2
This Week Only ⏰ Get 50% off UnKibble: - 100% human-grade ingredients - No fillers or preservatives - Vet-developed, complete recipes - Picky-eater approved - 1,700 5-star reviews
4
6
63
Do you have #AcuteMyeloidLeukemia (#AML) and are age 60 or older? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://t.co/lqKwON7qZ1
#leukemia #leusm
0
0
0
@SNM_MI @eaonc The results of the FEATURE trial (EA1183) were just presented by Dr. Jennifer Specht at SABCS25. In HR+ bone-only/bone-dominant metastatic breast cancer, FDG-PET/CT with modified PERCIST at 12 weeks prospectively predicted PFS. We can finally “measure the unmeasurable” and bring
0
2
6
Big news for breast imaging and nuclear medicine! A new study has demonstrated that metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation. More from @eaonc and @HJacene: https://t.co/oqTntrkGDQ
1
2
5
Have you ever seen a ball that flies? Christmas Offer ⏰ Only Time
16
37
509
#ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: https://t.co/NJBtg6CQfJ
0
0
0
FEATURE trial @ #SABCS25: FDG-PET/CT predicts therapy benefit@12wks in bone-dominant/only metastatic #breastcancer =earlier answers for patients+clinicaltrial eligibility TY @drjenspecht @UWMedicine @FredHutch & @HJacene @DanaFarber @BrighamWomens @theNCI
https://t.co/7wj58T6bDv
0
1
2
Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://t.co/4iFs1j4lU7 cc: @BalazsHalmosMD, @efratdotan, @CPresGeriOncMD
0
1
2
An #SABCS25 workshop explored breast cancer risk assessment and management in women under 40 years. Read about the session here: https://t.co/U0o9MPBC3t
0
4
5
Devs: ROCm 7.0 isn’t just ‘another’ upgrade. It’s your ticket to AI on your terms. Explore what ROCm 7 has to offer.
4
6
48
.@michael_lidsky of @DukeSurgOnc and @DukeCancer is leading EA2222/PUMP, a randomized phase 3 study for patients with #Colorectal liver metastases. Learn more: https://t.co/xBChV6GALe cc: @CCAlliance, @FightCRC, @NCCRTnews
0
2
2
ECOG-ACRIN & @CarisLS partner to train #AI models on data from 4k+ TAILORx trial cases, outperforming current tools to predict recurrence risk in early-stage #breastcancer. A big win for our public-private partnership & personalized care progress!
ecog-acrin.org
Learn why the new AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence...
0
2
4
#ClinicalTrial EA8231, led by @MonikaJoshimd & @PGrivasMDPhD, is a phase 3 randomized study exploring a new treatment approach for patients with treatment-refractory, locally-advanced or metastatic #UrothelialCancer. More information here: https://t.co/pAPr7iuYmR
0
0
1
Help potentially improve the future of #HeadAndNeckCancer treatment. Take part in clinical study EA3191 for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back. Learn more: https://t.co/0liEjdhnwI
#HNCA
0
0
0
Today during #SABCS25, researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN (@eaonc) and Caris focused on transforming recurrence risk assessment in early-stage breast cancer through AI. Learn more: https://t.co/15nc36RJjR
0
2
8
AI Model Improves Prediction of Early and Late Breast Cancer Recurrence, presented by @jsparano on behalf of @eaonc and @carisls public-pvivate partnership supported by @theNCI
@medpagetoday
medpagetoday.com
Joseph A. Sparano details multimodal approach outperforming the 21-gene recurrence score
0
0
1
📌GS1: Multimodal artificial intelligence (Al) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILOR× Joseph Sparano #SABCS25
@OncoAlert #OncoAlertAF
1
6
12
Caris’ multimodal AI research takes center stage this morning at #SABCS25. Don’t miss Dr. Joseph Sparano (@jsparano) presenting results from our innovative study on recurrence prediction and risk stratification in breast cancer. https://t.co/qsId8Zejp0
0
2
5
Don't miss @drjenspecht's abstract as part of the Rapid Fire 4 at #SABCS25 on 12/11 at 5:10 pm. Dr. Specht will present FDG-PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, ft. @eaonc
https://t.co/0aHpGuKSj7
@SABCSSanAntonio #ACRCRI
0
1
7